New approach aims to stop blood disorder from coming back
NCT ID NCT02979873
Summary
This study tests whether switching patients from cyclosporine to sirolimus helps prevent severe aplastic anemia from returning. Participants who responded well to previous immune-suppressing treatment will either switch to sirolimus or stop medication entirely, with close monitoring for relapse. The goal is to find a better way to maintain treatment benefits without lifelong cyclosporine use.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE APLASTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.